Cellumed Co

Cellumed Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Cellumed Co (049180.KQ) as of Nov 21, 2026 is -0.27. In the previous year, Total Debt to EBITDA Ratio was -0.26 — a change of 1.58% (lower).

Debt/EBITDA

-0.27

YoY

1.58%

Last updated:

Total Debt to EBITDA Ratio of Cellumed Co is 2024 -0.27 . Total Debt to EBITDA Ratio of Cellumed Co was 2023 -0.26 . It decreases by 1.58% lower compared to the previous year.

The Cellumed Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2017
112.42 KRW
Jan 1, 2018
-0.71 KRW
Jan 1, 2019
-0.19 KRW
Jan 1, 2020
1.89 KRW
Jan 1, 2021
0.35 KRW
Jan 1, 2022
-217.90 KRW
Jan 1, 2023
-0.26 KRW
Jan 1, 2024
-0.27 KRW
The Cellumed Co Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.27+1.58%
-0.26-99.88%
-217.90-61,636.39%
0.35-81.25%
1.89-1,080.11%
-0.19-72.92%
-0.71-100.63%
112.42-16,218.48%
-0.70-67.64%
-2.15+475.05%
-0.37—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellumed Co Stock analysis

What does Cellumed Co do? Cellumed Co Ltd manufactures and distributes medical devices and biomaterials, including allografts for tissue repair, bone sponges, bone powders, and demineralized bone matrixes (DBMs) for bone regeneration. The company also produces biosimilars like bone morphogenetic protein 2 (BMP2) reagents and medical devices such as spinal fixation systems, joint replacements, and navigation systems. Cellumed sells these products domestically in Seoul and internationally to overseas markets. Cellumed’s primary customers are healthcare providers and medical institutions that require tissue repair solutions, bone regeneration products, and advanced medical devices. The company’s product portfolio targets orthopedic and spinal care segments, with a focus on biomaterials and surgical tools. Its biosimilars, including BMP2 reagents, cater to specialized medical applications requiring bone growth stimulation. The company generates revenue through direct sales of its medical devices and biomaterials to hospitals, clinics, and international distributors. Cellumed’s domestic market in Seoul serves local healthcare facilities, while its overseas sales expand its reach to global medical markets. The firm’s product range supports both routine and complex surgical procedures in orthopedics and spinal care. Cellumed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellumed Co stock

Total Debt to EBITDA Ratio of Cellumed Co is -0.27 in 2024.

Total Debt to EBITDA Ratio of Cellumed Co changed from -0.26 to -0.27, representing a 1.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Cellumed Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Cellumed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cellumed Co

All Key Metrics — Cellumed Co